Researchers identify shield of cells that protects lung tumours from treatment
Researchers at the Francis Crick Institute, working with the Amsterdam University Medical Centre, have found that immune cells are held back from fighting lung tumours by another type of cell in the surrounding cellular neighbourhood.
Drugs that block a cancer-causing protein called KRAS-G12C are approved for use in lung cancer but often fail to work long-term because the tumours can develop resistance over time.
Scientists are now exploring the development of new combination treatment strategies to boost the immune system alongside blocking cancer-causing genes. But these will only work if immune cells are able to attack the cancer.
In new research published today in Science Advances, the researchers used a technique called imaging mass cytometry to see the distribution of immune cells around lung tumours in mice with KRAS mutations.
They saw that clusters of fighter cells called T cells were gathered near the tumours, as well as dendritic cells, which present signals to recruit more T cells to the site. When the mice were given a KRAS inhibitor drug, these cell communities grew in size and were able to enter the tumour.
However, they still couldn’t launch an immune response against the cancer cells. Using computational analysis of the cell clusters, the researchers could reveal that the cell community also contained regulatory T cells (Tregs), which were stopping immune cell coordination.
When the researchers blocked the action of Tregs, the mice responded better to the KRAS inhibitor, showing reduced tumour growth and longer survival.
The team concluded that Tregs are applying the brakes on an immune response, even where immune cells are present and ready to attack a tumour.
Julian Downward, Principal Group Leader of the Oncogene Biology Laboratory at the Crick, and senior author, said: “Lung cancer is one of the hardest types of cancer to treat, so working out how to harness the immune system to better target tumours is so important.
“Regulatory T cells are designed to stop the immune system from getting out of control, but it’s clear that they aren’t working as they should be next to cancer cells. Adding drugs that block Tregs to our combination treatments could help to reduce resistance to drugs like KRAS inhibitors.”
Blocking Tregs throughout the body could cause side effects as a result of the immune system becoming overactive, so the researchers are now exploring how to specifically block them in the tissues surrounding tumours.
Julian worked with first author Megan Cole, PhD student at the Crick, and Febe van Maldegem, Assistant Professor in the Department of Molecular Cell Biology and Immunology at Amsterdam University Medical Centre.
